Standout Papers

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced soli... 2018 2026 2020 2023 440
  1. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study (2018)
    Antoîne Italiano, Jean‐Charles Soria et al. The Lancet Oncology

Immediate Impact

3 from Science/Nature 55 standout
Sub-graph 1 of 23

Citing Papers

A high-fat diet promotes cancer progression by inducing gut microbiota–mediated leucine production and PMN-MDSC differentiation
2024 Standout
Transient loss of Polycomb components induces an epigenetic cancer fate
2024 StandoutNature
5 intermediate papers

Works of Stephen J. Blakemore being referenced

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
2018 Standout
302 A phase 1 study of EPZ-6438 (E7438), an Enhancer of Zeste-Homolog 2 (EZH2) inhibitor: Preliminary activity in INI1-negative tumors
2015
and 1 more

Author Peers

Author Last Decade Papers Cites
Stephen J. Blakemore 956 183 335 198 46 1.3k
Elspeth M. Beauchamp 1093 135 287 141 32 1.5k
Louis Hornez 773 91 403 201 41 1.3k
Mei Dong 1217 163 527 158 35 1.7k
Julia Calzada‐Wack 659 86 232 170 40 1.2k
Carolina Vicente‐Dueñas 712 166 490 202 41 1.2k
Toril Holien 988 367 327 93 47 1.5k
Dorina Gui 848 235 335 110 50 1.7k
Benedetta Peruzzi 572 115 209 127 36 1.1k
Jens Hasskarl 587 135 495 126 42 1.1k
Andreas Tobler 703 326 392 159 49 1.2k

All Works

Loading papers...

Rankless by CCL
2026